Department of Precision Medicine, University of Campania 'L. Vanvitelli', Naples, Italy.
Front Endocrinol (Lausanne). 2022 Feb 11;13:840787. doi: 10.3389/fendo.2022.840787. eCollection 2022.
Prostate cancer is the second most frequently diagnosed cancer in men and several therapeutic approaches are currently available for patient's care. Although the androgen receptor status represents a good predictor of response to androgen deprivation therapy, prostate cancer frequently becomes resistant to this approach and spreads. The molecular mechanisms that contribute to progression and drug-resistance of this cancer remain still debated. However, few therapeutic options are available for patient's management, at this stage. Recent years have seen a great expansion of the studies concerning the role of stromal-epithelial interactions and tumor microenvironment in prostate cancer progression. The findings so far collected have provided new insights into diagnostic and clinical management of prostate cancer patients. Further, new fascinating aspects concerning the intersection of the androgen receptor with survival factors as well as calcium channels have been reported in cultured prostate cancer cells and mouse models. The results of these researches have opened the way for a better understanding of the basic mechanisms involved in prostate cancer invasion and drug-resistance. They have also significantly expanded the list of new biomarkers and druggable targets in prostate cancer. The primary aim of this manuscript is to provide an update of these issues, together with their translational aspects. Exploiting the power of novel promising therapeutics would increase the success rate in the diagnostic path and clinical management of patients with advanced disease.
前列腺癌是男性中第二大常见的癌症,目前有几种治疗方法可用于患者的治疗。尽管雄激素受体状态是预测雄激素剥夺治疗反应的良好指标,但前列腺癌经常对这种方法产生耐药性并扩散。导致这种癌症进展和耐药性的分子机制仍存在争议。然而,在这个阶段,患者管理的治疗选择很少。近年来,关于基质-上皮相互作用和肿瘤微环境在前列腺癌进展中的作用的研究有了很大的扩展。迄今为止收集的研究结果为前列腺癌患者的诊断和临床管理提供了新的见解。此外,在培养的前列腺癌细胞和小鼠模型中,关于雄激素受体与生存因子以及钙通道交叉的新的迷人方面已经有报道。这些研究的结果为更好地理解前列腺癌侵袭和耐药性涉及的基本机制开辟了道路。它们还显著扩大了前列腺癌中新型生物标志物和可用药靶的清单。本文的主要目的是提供这些问题的最新进展及其转化方面的信息。利用新型有前途的治疗方法的力量将提高诊断路径和晚期疾病患者的临床管理的成功率。